 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Bradley Corr and Rebecca Wolsky.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.073 |
|
|
|
-
Ehimiaghe E, Marjon N, Post MD, Corr BR, Brubaker LW, Dimmick H, Ireigbe F, Bitler BG, Guntupalli SR, Behbakht K, Wolsky RJ. The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective. Gynecol Oncol. 2025 May 24; 198:55-58.
Score: 0.249
-
Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, Aisner DL, Wolsky RJ. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center. Int J Gynecol Pathol. 2024 Jul 01; 43(4):335-348.
Score: 0.222
-
Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer. bioRxiv. 2023 Apr 06.
Score: 0.215
-
Haag JG, Wolsky RJ, Moroney MR, Sheren J, Sheeder J, Bitler BG, Corr BR. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma. Int J Gynecol Pathol. 2023 Jan 01; 42(1):43-53.
Score: 0.199
-
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 08; 60(8):511-523.
Score: 0.189
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|